Increased Prescribing Accounts
Prescribing accounts increased by 15% in Q3, with approximately 150 new ordering accounts added, expanding the footprint to 1,150 accounts.
Improvement in New Patient Starts
New patient starts in the first and second line increased to 36%, up from 30% in Q2.
Strong Financial Position
Geron remains well-capitalized with $420 million in cash and marketable securities, and expects to have sufficient resources to fund projected operating expenses.
Presence at Medical Conferences
Active participation in hematology forums such as the Society of Hematologic Oncology Conference and upcoming ASH conference to increase RYTELO's awareness and engagement.